2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Sat, February 15, 2025 at 2:45 PM GMT+1 5 min read In This Article AZN VRTX Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN) , two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red. They're already doing better in 2025, though. And there are good reasons to think both could maintain a strong performance throughout the year. Here's why. VRTX data by YCharts 1. Vertex Pharmaceuticals Vertex Pharmaceuticals performed well for much of 2024. The stock slid during the year's final months, culminating in a massive one-day drop prompted by a clinical setback. In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- The Next Frontier Of Biohacking: Five Trends Poised To Redefine Health And Longevity [Forbes]Forbes
- Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio? [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- 3 Reasons to Avoid VRTX and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic FibrosisBusiness Wire
VRTX
Earnings
- 2/10/25 - Beat
VRTX
Sec Filings
- 3/13/25 - Form 144
- 3/12/25 - Form 4
- 3/12/25 - Form 4
- VRTX's page on the SEC website